Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Valneva SE (NASDAQ: VALN) experienced a significant drop of 14%, trading at $8.88 in pre-market sessions following the release of topline results from the Phase 3 VALOR clinical trial for its Lyme disease vaccine candidate PF-0730740, in collaboration with Pfizer (NYSE: PFE). Other stocks also fell, including LiveWire Group Inc (NASDAQ: LVWR) down 14.6% to $1.04, and Venture Global Inc (NYSE: VG) down 7% to $14.70 after announcing a new LNG purchase agreement.